Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse - A European pooled analysis

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2967-2976

  Janni, Wolfgang ^a   Vogl, Florian D ^e   Wiedswang, Gro ^f   Synnestvedt, Marit ^f   Fehm, Tanja ^b   Jückstock, Julia ^c   Borgen, Elin ^f   Rack, Brigitte ^c   Braun, Stephan ^g   Sommer, Harald ^c   Solomayer, Erich ^b   Pantel, Klaus ^d   Nesland, Jahn ^f   Friese, Klaus ^c   Naume, Bjørn ^f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e F Tappeiner Hospital   (Italy)

^f UNIVERSITY OF OSLO   (Norway)

^g UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TUMOR CELL;

AGED; BIOPSY; BONE MARROW; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; CARCINOMA; EUROPE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 79955491864     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2515     Document Type: Article

References (43)

1. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802. (Pubitemid 41215488)
2. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-8. (Pubitemid 26384811)
3. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001;19:3669-74. (Pubitemid 32786279)
4. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long- term follow-up study. Lancet 1999;354:197-202. (Pubitemid 29329158)
5. Wiedswang G, Borgen E, Kåresen R, Kvalheim G, Nesland JM, Qvist H, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-78. (Pubitemid 46594079)
6. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-40. (Pubitemid 351596394)
7. Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer 2005;103:884-91. (Pubitemid 40270064)
8. Wiedswang G, Borgen E, Kåresen R, Qvist H, Janbu J, Kvalheim G, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004;10:5342-8. (Pubitemid 39100469)
9. Singletary ES, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36. (Pubitemid 34983222)
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19: 403-10.
11. Le DV, Tubiana HM, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff- Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21.
12. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-8. (Pubitemid 28523434)
13. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001;19:3817-27. (Pubitemid 32880060)
14. Braun S, Pantel K, M€uller P, Janni W, Hepp F, Kentenich CR, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342: 525-33. (Pubitemid 30117892)
15. Janni W, Hepp F, Strobl B, Rack B, Rjosk D, Kentenich C, et al. Patterns of relapse influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus. Cancer 2003;97:405-11. (Pubitemid 36133807)
16. Naume B, Borgen E, Kvalheim G, Kåresen R, Qvist H, Sauer T, et al. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 2001;7:4122-9. (Pubitemid 34048337)
17. Pantel K, Schlimok G, Angstwurm M, Weckermann D, Schmaus W, Gath H, et al. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994;3:165-73.
18. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006;107:885-92. (Pubitemid 44291136)
19. Borgen E, Beiske K, Trachsel S, Nesland JM, Kvalheim G, Herstad TK, et al. Immunocytochemical detection of isolated epithelial cells in bone marrow: non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase. J Pathol 1998;185: 427-34. (Pubitemid 28355977)
20. Borgen E, Naume B, Nesland JM. Standardization of the immunocytochemical detection of cancer cells in BM and blood: establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;1:377-88.
21. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med 1996;15:1237-48.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
24. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
25. Dinh P, Cardoso F, Sotiriou C, Piccart-Gebhart MJ. New tools for assessing breast cancer recurrence. Cancer Treat Res 2008;141: 99-118.
26. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008;9:239.
27. Ignatiadis M, Sotiriou C. Understanding the molecular basis of histologic grade. Pathobiology 2008;75:104-11. (Pubitemid 351820728)
28. Fehm T, Mueller V, Marches R, Klein G, Gueckel B, Neubauer H, et al. Tumor cell dormanTumor cell dormancy: implications for the biology and treatment of breast cancer. APMIS 2008;116:742-53.
29. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68. (Pubitemid 350309740)
30. Fehm T, Becker S, Becker-Pergola G, Sotlar K, Gebauer G, Dürr- Störzer S, et al. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer. Breast Cancer Res 2006;8:R60.
31. Pantel K, Schlimok G, Kutter D, Schaller G, Genz T, Wiebecke B, et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991;51:4712-5.
32. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-24. (Pubitemid 23264351)
33. Rack B, Schindlbeck C, Strobl B, Sommer H, Friese K, Janni W. Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 2008;133:285-9. (Pubitemid 351315392)
34. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91. (Pubitemid 39095313)
35. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
36. Cristofanilli M, Mendelsohn J. Circulating tumor cells in breast cancer: advanced tools for "tailored" therapy?Proc Natl Acad Sci U S A 2006;103:17073-4.
37. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004-10.
38. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20:3404-12.
39. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009;27:2177-84.
40. Rack B, Schindlbeck C, Andergassen U, Lorenz R, Zwingers T, Schneeweiss A, et al. for the SUCCESS Study Group. Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients. Rack B, SABCS 2010 Supp. Cancer Research 201;70:S6-5.
41. Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004;10:1392-400.
42. Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006;94:672-80. (Pubitemid 43361898)
43. Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G, Nesland JM, et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2006;118:2013-9.